模拟计算机断层扫描引导的立体定向自适应放疗(CT-STAR)治疗局部晚期胰腺癌
一项前瞻性在体成像临床试验,8例局部晚期胰腺癌患者在标准放疗前后额外接受5次CBCT,基于初始模拟解剖制定计划(PI),基于当日解剖生成自适应计划(PA),处方剂量50 Gy/5次。CT-STAR在体可行,100%分次改善危及器官和/或靶区剂量学,39/40次PA满足所有OAR约束。
要点
- 8例局部晚期胰腺癌患者接受额外5次CBCT,处方50 Gy/5次,采用严格等毒性方法优先满足OAR约束。
- CT-STAR在体可行,100%分次改善OAR和/或靶区剂量学。
- 基于当日解剖的PI导致94次OAR约束违反,40/40分次至少1项硬约束违反;39/40次PA满足所有OAR约束。
核心结论
- CT-STAR治疗局部晚期胰腺癌在体可行,剂量学优于非自适应CT-立体定向体部放疗。
研究设计与样本
- 前瞻性在体成像临床试验,8例局部晚期胰腺癌患者在标准放疗前后额外接受5次CBCT,基于初始模拟解剖制定计划(PI),基于当日解剖生成自适应计划(PA),处方50 Gy/5次。
主要发现
- CT-STAR在体可行,100%分次改善危及器官和/或靶区剂量学。
- 基于当日解剖评估PI导致总计94次OAR约束违反,40/40分次至少1项硬约束违反。
- 39/40次PA满足所有OAR约束;1次PA轻度超过大肠约束,但剂量学优于PI。
- 每分次总工作流程时间为36.28分钟(27.57-55.86)。
关键数值与推荐
- 可行性定义为≥80%分次成功完成工作流程并符合严格OAR约束。
- 处方剂量为50 Gy/5次。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We conducted a prospective, in silico imaging clinical trial to evaluate the feasibility and potential dosimetric benefits of computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer (LAPC). MATERIALS AND METHODS: Eight patients with LAPC received five additional CBCTs on the ETHOS system before or after their standard of care radiotherapy treatment. Initial plans were created based on their initial simulation anatomy (PI) and emulated adaptive plans were created based on their anatomy-of-the-day (PA). The prescription was 50 Gy/5 fractions. Plans were created under a strict isotoxicity approach, in which organ-at-risk (OAR) constraints were prioritized over planning target volume coverage. The PI was evaluated on the patient's anatomy-of-the-day, compared to the daily PA, and the superior plan was selected. Feasibility was defined as successful completion of the workflow in compliance with strict OAR constraints in ≥80% of fractions. RESULTS: CT-STAR was feasible in silico for LAPC and improved OAR and/or target dosimetry in 100% of fractions. Use of the PI based on the patient's anatomy-of-the-day would have yielded a total of 94 OAR constraint violations and ≥1 hard constraint violation in 40/40 fractions. In contrast, 39/40 PA met all OAR constraints. In one fraction, the PA minimally exceeded the large bowel constraint, although dosimetrically improved compared to the PI. Total workflow time per fraction was 36.28 minutes (27.57-55.86). CONCLUSION: CT-STAR for the treatment of LAPC cancer proved feasible and was dosimetrically superior to non-adapted CT-stereotactic body radiotherapy.
引用
- Schiff JP, Price AT, Stowe HB, et al. Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer. Radiother Oncol. 2022. PMID: 36063981. doi:10.1016/j.radonc.2022.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。